Some of the leading companies operating in the global cancer immunotherapy market are Bristol-Myers Squibb Company, Amgen, Inc., GlaxoSmithKline Plc., AstraZeneca Plc., and F. Hoffmann-La Roche Ltd.,
According to a report by Transparency Market Research, the market is expected to be fragmented in nature as there are various small and large companies operating in the market. Introduction of new drugs are resulting in competition rivalry among the existing companies. Key players in the market are engaging in research and development activities that have resulted in innovation of drugs that have antibody dependent cellular toxicity, antigen specificity, and adaptive immunity.
The global cancer immunotherapy market is expected to grow rapidly with a rising CAGR of 14.6% during the forecast period of 2016 to 2024. The global market was worth US$37.50 bn during 2015 and is expected to attain a valuation of US$124.88 bn by the end of 2024. The global cancer immunotherapy therapy segment is led by breast cancer. Among all regions, North America is leading the cancer immunotherapy market by bagging the larger share in the market by the end of 2024. This region is expected to dominate the market in the during the forecast period owing to increasing development in this region.
Request A Sample-
Increase in Patient Assistance Program to Boost the Market
The global cancer immunotherapy market is rising among various regions because it is more effective than conventional treatments. Rise in cancer due to unhealthy lifestyle and other factors are most likely to boost the market for cancer immunotherapy. The market is expected to experience high development owing to launch of new treatment methods and drugs in the pipeline. There is an increasing number of patient assistance program which is likely to boost the market for cancer immunotherapy. Rise in requirement of cancer monoclonal antibodies is another reason for rise in cancer immunotherapy.